News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Roivant Sciences’ (Nasdaq:ROIV) $200 Million Follow-On OfferingFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Avalo Therapeutics’ (Nasdaq: AVTX) $15 Million Follow-On OfferingFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Olink’s (Nasdaq: OLK) $117 Million Follow-On OfferingJanuary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Fulcrum Therapeutics’ (Nasdaq: FULC) $125 Million Follow-On OfferingJanuary 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to AMF Medical SA on its Sale to Tandem Diabetes Care, Inc. (Nasdaq: TNDM)December 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Replimune’s (Nasdaq: REPL) $225 Million Follow-On OfferingDecember 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Prometheus Biosciences’ (Nasdaq: RXDX) $500 Million Follow-On OfferingDecember 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner to Lantheus (NASDAQ: LNTH) on its $500 Million Rule 144A Offering of Convertible Senior NotesDecember 2022
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Aura Biosciences’ (Nasdaq: AURA) $80 Million Follow- On OfferingDecember 2022
News | Deal AnnouncementSVB Securities Served as PIPE Placement Agent to Frazier Lifesciences Acquisition Corp. (Nasdaq: FLAC) and Financial Advisor and Capital Markets Advisor to NewAmsterdam Pharma in Connection with its Completed Merger and $235 Million PIPENovember 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Surgery Partners’ (Nasdaq: SGRY) $575 Million Public Offering of Common StockNovember 2022